youtube_live
Q3 2026 earnings • released • EPS beat +304.81% • Revenue beat +0.22%
See resultschevron_right
BMRN:NASDAQ
Biomarin Pharmaceutical Inc
$57.44
arrow_downward
-1.83%(-1.07) 1D
$54.50
arrow_downward
-5.12% (-2.94)bedtimeAfter hours
Closed: Nov 2, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BMRN...
Open
$58.66
High
$59.51
Low
$57.17
Mkt. cap
11.12B
Avg. vol.
2.34M
Volume
3.26M
P/E ratio
154.85
52-wk high
$70.98
52-wk low
$49.26
EPS
$0.37
Beta
0.22
Shares outstanding
193.57M
No. of employees
3K
Open
$58.66
High
$59.51
Low
$57.17
Mkt. cap
11.12B
Avg. vol.
2.34M
Volume
3.26M
P/E ratio
154.85
52-wk high
$70.98
52-wk low
$49.26
EPS
$0.37
Beta
0.22
Shares outstanding
193.57M
No. of employees
3K
News stories
From web sources and news partners
Yahoo Finance
·
45 minutes ago
BioMarin Pharmaceutical Q3 Earnings Call Highlights
Yahoo Finance Australia
·
50 minutes ago
BioMarin Pharmaceutical (BMRN) Could Be 21% Undervalued On Mixed Q3 Guidance Cut
Yahoo Finance
·
1 hour ago
BioMarin (BMRN) Stock May Be A Bargain After Fabry Therapy Deal
Investing.com UK
·
2 hours ago
Earnings call transcript: BioMarin tops Q3 2026 estimates, but shares fall
Profile
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
About Biomarin Pharmaceutical Inc
CEOAlexander Hardy
Employees3.22K
FoundedMar 1997
HeadquartersSan Rafael, California, United States
SectorBiotechnology
Websitebiomarin.com